Effect of Angiotensin II Type 1 Receptor Antagonist, Losartan on Inflammatory Factor in Atherosclerotic Rabbits

Yan-min Xu 1,*, Deepak Sharma 1, Guang-ping Li 1, Ya-Nan Zhao 1

1 Department of Cardiology, Tianjin Medical University, Tianjin, Republic of China

*Corresponding author: Yan-min Xu, Department of Cardiology, Tianjin Medical University, Tianjin, Republic of China. Tel: +86-2288328339, Fax: +86-2228261158, E-mail: xuyanmin@eyou.com

ABSTRACT

Background: Atherosclerosis is a progressive disease characterized by the accumulation of lipids and fibrous elements in the large arteries which now has become the pre-eminent health problem worldwide.

Objectives: To investigate the effect and mechanism of Losartan intervention on atherosclerosis in rabbits fed with high-cholesterol diet.

Materials and Methods: 32 New Zealand rabbits were randomly divided into three groups: control group, high-cholesterol group and Losartan group. The level of weights, serum lipid levels and inflammatory factors, such as IL-6 and hs C-reactive protein were detected before the Losartan intervention and two months after the Losartan intervention respectively. The content of AngII was detected on later stage of the experiment. Pathological examination of the iliac arteries was performed to measure the thickness of endothelium and media.

Results: After the atherosclerosis model was established, the level of the serum lipids, hs CRP and IL-6 of rabbits in high-cholesterol group and Losartan group increased significantly in comparison with control group (P < 0.05), but there was no statistical difference between the two groups (P > 0.05). After the Losartan intervention, the levels of serum hs CRP and IL-6 were higher in high-cholesterol group and Losartan group in comparison with control group (P < 0.05), and they were significantly lower in Losartan group than high-cholesterol group (P < 0.05). Serum lipids levels of rabbits in high-cholesterol group and Losartan group also increased significantly in comparison with control group (P < 0.05), but there was no statistical difference between them (P > 0.05). Ratio of endothelium thickness to the media thickness was higher in high-cholesterol group and Losartan group in comparison with control group (P < 0.05), and the ratio in Losartan group was significantly lower than high-cholesterol group (P < 0.05). Content of Angiotensin was higher in high-cholesterol group and Losartan group compared to control group, and there was no statistical difference between them.

Conclusions: The effect of Losartan on atherosclerosis is to prevent the development of atherosclerosis by inhibiting inflammatory process and may not be related to the lipid metabolism.

Keywords: Atherosclerosis; Losartan; C-reactive protein; Interleukin-6; AngiotensinII
1. Background

Atherosclerosis is a progressive disease characterized by the accumulation of lipids and fibrous elements in the large arteries which now has become the pre-eminent health problem worldwide (1). Over the past few years, we have increased the understanding of the importance of inflammation during all stages of atherosclerosis, from its inception through its progression and its final complication of thrombosis (2, 3). A few studies have showed that the renin-angiotensin system (RAS) participates in the pathogenesis of atherosclerosis (AS) process, angiotensin II (AngII) which is the main active factor in renin-angiotensin system improves the absorption of oxidized low density lipoprotein through a combination with the cell membrane of AngII receptor, affects fibrinolysis function of vascular endothelium and inflammation, and thereby accelerates the occurrence and development of AS (4, 5).

2. Objectives

In the present study, we explore the effect of Losartan on inflammation factors, such as hs CRP, IL-6 and the level of serum lipids to investigate possible mechanisms of Losartan effects in anti-AS.

3. Materials and Methods

3.1. Experimental Animals

We declare that there are no human subjects including human material or human data involved. We also clarify that our study (and the protocol used) has been approved by our institutional animal ethics committee. The level of weights, lipids and inflammatory factors, such as IL-6 and hs C-reactive protein and the content of Angiotensin in iliac arteries which were checked in our study have been approved by our institutional animal ethics committee.

32 healthy purebred New Zealand rabbits weighing from 2.1 kg, aging from 3 to 4 months were randomly divided into three groups: 1) The control group (n = 11) were on diet of normal diet; 2) high fat group (n = 11) were on high diet of cholesterol and saturated fat diet containing 1% cholesterol plus 5% lard plus 10% egg yolk powder and 84% normal diet; 3) Losartan group (n = 10) were on the same diet with high fat group.

3.2. Experimental Procedure

Rabbits were pre-anesthetized with xylazine hydrochloride (4 mg/kg IM.). After 20 minutes, anesthesia was induced with a bolus injection of sodium pentobarbital (10 mg/kg IV) and maintained with supplementary injections of 2 ± 4 mg/kg doses as required. Under sterile conditions the right femoral artery was isolated and an arched incision of length in knee region was made. When a femoral arteriotomy was performed, a 0.014 inch guide wire to the artery was sent; thereafter, the balloon was inflated with saline to a pressure of 8-12 atm and inserted with a depth of 12 of artery. The balloon was removed from the artery incision and location of balloon was changed to make intima-injury, the process was repeated for 3 times. The high fat group and Losartan group undergo balloon-injury of right iliac artery intima before feeding. After 4 weeks, all rabbits were weighed and their serum lipid levels and inflammatory markers were measured. Then, the Losartan group were fed 25mg/kg Losartan orally which continued with an 8 week interval. After 12 weeks, the weighing and measurement were repeated. Finally iliac arteries were partially removed and reserved for pathological analysis.

3.3. Measurement of Serum Samples

Blood samples were collected at the 4th week and 12th week (8 weeks after losartan intervention). The lipid level was measured using enzymatic method by Selectra-E automatic biochemical analyzer; IL-6 and hs CRP were measured using enzyme-linked immunosorbent assay (ELISA) kits. AngII was measured using radioimmunoassay kits.

3.4. Determination of Intima to Media Thickness Ratio

All vessel sections were stained with haematoxylin and eosin. Measurements were made of cross-sectional thickness of the lumen and enclosed by the internal and external elastic laminar. The intimal cross-sectional thickness of femoral artery segments was determined by subtracting the thickness of the lumen from the thickness enclosed by the internal elastic lamina. The medial thickness was determined by subtracting the thickness enclosed by the internal elastic lamina from the thickness enclosed by the external elastic lamina. The Image-Pro Plus 6.0 image analysis system was used to measure intima and media thickness and calculate the ratio.

3.5. Statistical Analysis

All data processing statistics are used SPSS 13.0. Continuous variables are expressed as mean ± standard deviation. Statistical analysis was performed by one-way analysis of variance (ANOVA) among groups. For comparison of data before and after dietary and drug intervention, a paired t test was used. We considered p < 0.05 to be statistically significant.

4. Results

4.1. Effects of Losartan on Serum Lipid

In the fourth and twelfth week, the serum lipid of rabbits in high fat group and Losartan group increased significantly compared with control group (P < 0.05). But there was no statistical difference between the two
groups. Serum lipid levels at the twelfth week were higher than the fourth week in high fat group and Losartan group (P < 0.05) (Table 1).

Table 1. The TG, TC and LDL-C Levels of Serum in Different Groups and Different Periods (mmol/L, means ± SD)

|                     | Control Group (n=11) | High Lipid Group (n=11) | Losartan Group (n=10) |
|---------------------|----------------------|-------------------------|-----------------------|
| 4 w                 | 0.82± 0.20           | 12.89± 8.35             | 12.88± 9.58           |
| TC                  | 1.77± 0.62           | 51.98± 15.84            | 45.23± 15.80          |
| LDL-C               | 1.02± 0.60           | 22.56± 6.92             | 19.61± 5.95           |
| 12 w                | 0.85± 0.27           | 27.72± 18.44            | 24.88± 15.07          |
| TC                  | 1.70± 0.64           | 69.81± 18.24            | 67.84± 13.72          |
| LDL-C               | 1.04± 0.60           | 29.59± 7.87             | 29.84± 7.56           |

a Compared with Control Group, P < 0.05
b Compared with High Fat Group, P > 0.05

4.2. Effects of Losartan on IL-6 and hs CRP

In the fourth week, IL-6 and hs CRP levels of rabbits in high fat group and Losartan group increased significantly in comparison with control group (P < 0.05). But there is no statistical difference between the two groups. In the twelfth week, IL-6 and hs CRP level of rabbits in high fat group and Losartan group also increased significantly in comparison with control group (P < 0.05). But IL-6 and hs CRP level in Losartan group was lower than high fat group (P < 0.05). IL-6 and hs CRP levels at the twelfth week were lower than the fourth week in Losartan group (P < 0.05). But IL-6 and hs CRP levels at the twelfth week had no significant difference compared with the fourth week in high fat group and control group (P > 0.05) (Table 2).

Table 2. The Level of hs CRP and IL-6 in Different Groups of Different Periods (mean ± SD)

|                     | Control Group (n=11) | High Lipid Group (n=11) | Losartan Group (n=10) |
|---------------------|----------------------|-------------------------|-----------------------|
| CRP (pg/ml)         | 2.86± 0.38           | 4.30± 0.32               | 4.53± 0.36            |
| 4 w                 |                      |                         |                       |
| IL-6 (pg/ml)        | 2.87± 0.34           | 4.60± 0.33               | 3.34± 0.38            |
| 12 w                | 19.10± 19.16         | 98.00± 19.56             | 101.78± 16.56         |
| 4 w                 | 27.00± 18.14         | 97.40± 18.41             | 58.56± 13.06          |

a Compared with Control Group, P < 0.05
b Compared with High Lipid Group, P > 0.05
c Compared with High Fat Group, P < 0.05

4.3. Effects of Losartan on AngII Level

AngII level was higher in high fat group and Losartan group in comparison with control group (P < 0.05). However, there were no statistical differences between the two groups, discussed above (P > 0.05) (Table 3).

Table 3. The Level of AngII in Vascular Tissue (pg/mg mean ± SD)

|                      | Control Group (n=11) | High Fat Group (n=11) | Losartan Group (n=10) |
|----------------------|----------------------|-----------------------|-----------------------|
| Ang II               | 73.397± 9.511        | 134.367± 60.244       | 133.979± 62.440       |

a Compared with Control Group, P < 0.05
b Compared with High Fat Group, P > 0.05

4.4. Effect of Losartan on the Ratio of Intima Thickness

Processing of image analysis system showed that the ratio of intima thickness to the media thickness were higher in high fat group and Losartan group, compared to control group (P < 0.05), and the ratio in Losartan group was lower than high fat group (P < 0.05) (Table 4), (Figure 1). In left is the control group, in middle is high fat group and in right is Losartan group. The ratio in Losartan group was lower than high fat group.

5. Discussion

Renin-angiotensin-aldosterone (RAA) system is the complex neuroendocrine system and regulates vascular tone and salt metabolic balance. Studies have shown that RAA system exists in local vascular and in many pathological situations its activity increases (6-8). AngII on vascular wall cells and extracellular matrix, changes the expression of the inflammatory cytokines, chemokines and adhesion molecules, leading to endothelial dysfunction, promotes lipid deposition and inflammation, eventually leading to the formation of atherosclerosis (9, 10).

This study shows that high fat group has obvious plaque on arterial wall, lumen narrowing and the elastic membrane stretching and fracturing. Outer membrane did not change. The ratio of intima to media is nine times than the ratio of the control group. The degree of atherosclerosis in Losartan group was alleviated compared with high fat group. The ratio of intima to media was reduced by about 1 time compared with the high fat group. In the current study for the first time, we demonstrate that treatment with the Losartan may play a role against atherosclerosis.

At the end of the treatment period, we observed a significant increase of serum lipid and AngII in high fat group and Losartan group than the one in control group, but there was no difference between the two groups. We also observed a significant decrease in the level of blood hs CRP and IL-6, a pro-inflammatory cytokines in Losartan group. Therefore, the results suggest that hyperlipidemia activates RAAS and increases AngII to promote the formation of atherosclerosis and also suggest that the anti-atherosclerosis effects of Losartan does not include reducing AngII and lipid-lowering effect, but an there exists an anti-inflammatory effect of Losartan the atheroclerosis...
Effect of Angiotensin II Type 1 Receptor Antagonist

Xu Y et al.

Losartan may be acting on inhibiting protein of nuclear factor κB and lead MCP-1, VCAM-1, E-selection in adhesion process to reduce, inhibiting the inflammatory response in occurrence of atherosclerosis (15, 16). Hence, further study is required to be done. As our study, we assume, the inhibiting inflammatory process is the primary function of Losartan on atherosclerosis to prevent the development of atherosclerosis. In short, the formation of atherosclerosis is the result of multiple factors. AT1 receptor antagonist (Losartan) not only reduces blood pressure by reverse ventricular remodeling but also inhibits the occurrence and development of atherosclerosis. The effect of Losartan on atherosclerosis is to prevent the development of atherosclerosis by inhibiting inflammatory process and may not be related to the lipid metabolism.

Table 4. The Ratio of Intima to the Media of Three Groups (mean ± SD)

|                  | Control Group | High Fat Group | Losartan Group |
|------------------|---------------|----------------|----------------|
| Intima/media     | 0.208 ± 0.082 | 1.864 ± 0.556<sup>a</sup> | 1.098 ± 0.493<sup>b</sup> |

<sup>a</sup> Compared with Control Group, P < 0.05
<sup>b</sup> Compared With High Fat Group, P < 0.05

Acknowledgments
None declared.

Authors’ Contribution
We declare that all the authors participated in the design of the study and performed the statistical analysis. All authors read and approved the final manuscript. Pro. Yanmin xu, deepark sharma, guangping li and yanan zhao have made substantive intellectual contributions to a published study. Yanmin xu have made substantial contributions to conception and design, deepark sharma have made substantial contributions to acquisition of data, analysis and interpretation of data; guang ping li have involved in drafting the manuscript and revising it critically for important intellectual content; Yanmin xu and yanan zhao have given final approval of the version to be published.

Financial Disclosure
All authors declare that there is no financial disclosure.

Funding Support
This article is partly supported by Tianjin Health Bureau Scientific Foundation.

References
1. Libby P. Atherosclerosis: the new view. Sci Am. 2002;286(5):46-55.
2. Mestas J, Ley K. Monocyte-endothelial cell interactions in
the development of atherosclerosis. Trends Cardiovasc Med. 2008;18(6):228-32.
3. Garcia-Moll X. [Inflammation, atherosclerosis, classic cardiovascular risk factors, biostatistics, clinical significance. Where are we?]. Rev Esp Cardiol. 2007;60(12):1220-2.
4. Papademetriou V. The potential role of AT(1)-receptor blockade in the prevention and reversal of atherosclerosis. J Hum Hypertens. 2002;16 Suppl 1:S34-41.
5. Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kohler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19(7):1623-9.
6. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996;94(10):2756-67.
7. Ohishi M, Ueda M, Rakugi H, Okamura A, Naruko T, Becker AE, et al. [Upregulation of angiotensin-converting enzyme during the healing process after injury at the site of percutaneous transluminal coronary angioplasty in humans]. J Cardiol. 1998;31(3):185-6.
8. Ford CM, Li S, Pickering JG. Angiotensin II stimulates collagen synthesis in human vascular smooth muscle cells. Involvement of the AT(1) receptor, transforming growth factor-beta, and tyrosine phosphorylation. Arterioscler Thromb Vasc Biol. 1999;19(8):2843-51.
9. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation. 2009;119(3):448-54.
10. Miyazaki M, Sakonjo H, Takai S. Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet. Br J Pharmacol. 1999;128(3):523-9.
11. Ikeda H, Minamikawa J, Nakamura Y, Honjo S, Hamamoto Y, Wada Y, et al. Comparison of effects of amloidipine and angiotensin receptor blockers on the intima-media thickness of carotid arterial wall (AAA study: amloidipine vs. ARB in atherosclerosis study). Diabetes Res Clin Pract. 2009;83(1):50-3.
12. Liang C, Wu ZG, Ding J, Jiang JJ, Huang GZ, Du RZ, et al. Losartan inhibited expression of matrix metalloproteinases in rat atherosclerotic lesions and angiotensin II-stimulated monocytes. Acta Pharmacol Sin. 2004;25(1):34-26-32.
13. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol. 2000;20(3):645-51.
14. Liu YL, Liu GT. The inspiration of relationship between vascular endothelial cell inflammatory response and atherosclerosis on drug research. Chinese Pharmacology Bulletin. 2001;17(4):436-434.
15. Prasad A, Koh KK, Schenke WH, Mincemoyer R, Csako G, Fleischer TA, et al. Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. Am J Heart. 2001;144(2):248-53.
16. Allen CL, Bayraktutan U. Differential mechanisms of angiotensin II and PDGF-BB on migration and proliferation of coronary artery smooth muscle cells. J Mol Cell Cardiol. 2008;45(2):598-208.